Influenza is an acute, febrile respiratory illness of global importance caused by serotypes A, B, and C of the influenza virus. In a typical season, the disease affects 5 to 40 of the population. In the United States, it is estimated that an average of approximately 110, 000 hospitalizations per year and 20, 000 deaths are related to complications of the illness. Elderly people, very young children, and patients with chronic cardiopulmonary conditions are at highest risk for developing influenza.74 Because of their ability to mutate and their potential to move from animal reservoirs to humans, influenza viruses are able to emerge or re-emerge as new viruses with the potential of spreading rapidly through susceptible populations and causing worldwide epidemics or pandemics of influenza. The three most important pandemics caused by influenza viruses during the twentieth century were the pandemic of 1918 and 1919, with 2 billion people affected and 20 to 40 million deaths; the 1957 Asian influenza pandemic, and the 1968 pandemic of Hong-Kong influenza.22 The development of new therapeutic options for individuals with respiratory viral infections and the need to limit unnecessary antimicrobial use have resulted in the generation of new diagnostic tests for influenza. These methods range from classic tissue culture to modern molecular procedures. Vaccination with the currently available trivalent inactivated influenza vaccine is the most effective preventive measure for reducing the impact of influenza during epidemics and pandemics of the disease. During recent years, some Latin American countries have carried out important programs and vaccination campaigns in the elderly and other high-risk groups. These efforts have allowed us to obtain estimates of vaccine effectiveness and the adverse effects of inactivated influenza vaccine, and they have proved to be useful in improving immunization coverage in these populations. The new live attenuated cold-adapted vaccines, which are delivered intranasally, may help to prevent the spread of the disease if they become available in the near future.11, 89 The current antiviral drugs (amantadine and rimantadine) may be used against influenza A infections. The advantages of the new neuraminidase inhibitors are their ability to stop viral replication in influenza A and B viruses, their usefulness in treating severe infection, and their potential to reduce the risk of complications.40, 41 The purpose of this article is to present summarized, categorized, and updated information on influenza. The authors hope that this knowledge will contribute to the prevention and adequate management of the disease.

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/1968/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000139 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/1968/Analysis/biblio.hfd -nk 000139 | SxmlIndent | more

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    1968
   |étape=   Analysis
   |type=    RBID
   |clé=     ISTEX:F94D24F0FC3C1CC17BCD497DB130E01F3983907D
   |texte=   INFLUENZA
}}